Matt Abernethy is CFO at NEUROCRINE BIOSCIENCES INC (NBIX). They have made 14 open-market trades across 1 company since 2018, most recently 2026-09-14.
CIK 0001724097
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NBIX | 42,808 | $7.1M |
Shares reported on the most recent Form 4, priced at the 2026-09-15 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NBIX | SELL · 10b5-1 | 2026-09-14 | 2026-09-15 | $157.20 | $363K | -7.7% | -8.7% | — |
| NBIX | SELL · 10b5-1 | 2025-02-13 | 2025-02-14 | $116.86 | $598K | +2.2% | -3.1% | +4.6% |
| NBIX | SELL · 10b5-1 | 2025-02-10 | 2025-02-12 | $118.27 | $232K | -1.2% | -5.6% | -0.4% |
| NBIX | SELL · 10b5-1 | 2025-01-31 | 2025-02-04 | $152.87 | $392K | -24.2% | -25.7% | -27.6% |
| NBIX | SELL · 10b5-1 | 2024-08-13 | 2024-08-15 | $150.38 | $2.1M | +3.8% | -16.8% | -14.6% |
| NBIX | SELL · 10b5-1 | 2024-07-16 | 2024-07-18 | $150.04 | $135K | -2.3% | +2.6% | -18.1% |
| NBIX | SELL · 10b5-1 | 2024-05-14 | 2024-05-16 | $137.95 | $4.1M | -5.2% | -4.7% | +3.3% |
| NBIX | SELL · 10b5-1 | 2024-02-13 | 2024-02-15 | $132.85 | $359K | +0.4% | +3.9% | +5.9% |
| NBIX | SELL · 10b5-1 | 2024-02-06 | 2024-02-08 | $138.73 | $627K | -3.0% | +2.9% | +3.2% |
| NBIX | SELL · 10b5-1 | 2024-01-31 | 2024-02-02 | $140.72 | $361K | -6.7% | -5.7% | -1.0% |
| NBIX | SELL · 10b5-1 | 2023-08-21 | 2023-08-23 | $107.39 | $458K | +2.1% | +5.6% | +1.8% |
| NBIX | SELL | 2023-02-06 | 2023-02-08 | $102.61 | $5.9M | -2.5% | -8.5% | -7.2% |
| NBIX | SELL | 2023-01-31 | 2023-02-02 | $109.98 | $282K | -5.8% | -7.8% | -9.8% |
| NBIX | SELL | 2022-02-07 | 2022-02-09 | $80.59 | $449K | +10.7% | +12.7% | +3.8% |
| NBIX | SELL | 2021-12-01 | 2021-12-03 | $82.59 | $272K | +7.1% | +11.9% | +10.9% |
| NBIX | SELL | 2021-02-08 | 2021-02-09 | $116.82 | $577K | -4.3% | -18.5% | -21.3% |
| NBIX | SELL | 2020-12-01 | 2020-12-02 | $94.66 | $311K | -3.6% | -1.1% | +4.7% |
| NBIX | SELL | 2020-11-12 | 2020-11-16 | $90.74 | $410K | +3.1% | +6.5% | +21.3% |
| NBIX | SELL | 2020-08-05 | 2020-08-07 | $118.90 | $537K | -1.6% | -4.5% | -12.7% |
| NBIX | SELL | 2020-05-07 | 2020-05-11 | $110.21 | $1.7M | +5.6% | +3.2% | -1.9% |
| NBIX | SELL | 2020-04-28 | 2020-04-30 | $102.49 | $357K | +16.1% | +27.3% | +24.7% |
| NBIX | SELL | 2020-04-24 | 2020-04-28 | $99.52 | $385K | +9.0% | +19.8% | +25.5% |
| NBIX | SELL | 2020-02-07 | 2020-02-11 | $103.35 | $420K | -9.5% | -24.4% | +6.0% |
| NBIX | SELL | 2019-12-02 | 2019-12-04 | $116.33 | $383K | -8.5% | -7.6% | -22.1% |
| NBIX | SELL | 2018-12-03 | 2018-12-06 | $90.00 | $106K | -17.6% | -5.3% | -12.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.